Submit a Request

Topic: Data & Statistics

Tobacco Use and Smoking Cessation Among People with Substance Use Disorders: A Summary of the State of the Science and New Evidence from Nevada

Over 80% of people with substance use disorders (SUDs), including opioid use disorder (OUD), smoke cigarettes. While smoking prevalence has decreased in the general population, it remains stubbornly high among people with opioid use disorder (OUD) and other substance use disorders (SUDs). Evidence suggests that conventional smoking cessation treatments are not as successful for people with SUDs as they are in the general population. This training will present the most recent epidemiology on smoking and use of cessation aids among people with SUDs, summarize the state of the science concerning smoking cessation treatment in this population, and present new data from Nevada on a smoking harm minimization intervention using e-cigarettes.

An Overview of Opioid Use: Recent Trends, Emerging Substances and Strategies for Providers

This one-hour video will provide an overview of emerging opioids and related substances. Providers working in local communities need to be prepared for emerging substances and how they can complicate the response to opioid overdose. The session will begin with a description of opioid trends and emerging substances such as xylazine and nitazines, including mechanisms of action and acute health effects when substances are combined. The presentation will incorporate a discussion on how to implement effective approaches for emerging substances and strategies for overcoming barriers.

Community Response and Best Practices for Opioid Antagonists

Learning Objectives: 

By the end of this training people will know:

 The history of overdose prevention and opioid antagonist distribution for community members, including available formulations of antagonists

State of the research on opioid antagonist distribution, utilization, and outcome in the community

Evidence-based practices for overdose response and opioid antagonist administration